^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
M9140
i
Other names: M9140
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EMD Serono
Drug class:
Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate
Related drugs:
1m
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
Trial completion date • Trial primary completion date • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Avastin (bevacizumab) • capecitabine • M9140
2ms
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Avastin (bevacizumab) • capecitabine • M9140
almost2years
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, EMD Serono Research & Development Institute, Inc.
New P1 trial
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
M9140
Share via
